<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00083109</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02586</org_study_id>
    <secondary_id>NCI-2012-02586</secondary_id>
    <secondary_id>CCF-6101</secondary_id>
    <secondary_id>NCI-6036</secondary_id>
    <secondary_id>CDR0000363559</secondary_id>
    <secondary_id>CWRU-CASE-1804</secondary_id>
    <secondary_id>IRB 6101</secondary_id>
    <secondary_id>6036</secondary_id>
    <secondary_id>R01CA093871</secondary_id>
    <secondary_id>U01CA062502</secondary_id>
    <nct_id>NCT00083109</nct_id>
  </id_info>
  <brief_title>Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidney) Cancer</brief_title>
  <official_title>Phase I/II Trial Of Low Dose Suramin (CI-1003, NSC#34936) And 5-Fluorouracil In Patients With Metastatic Renal Cell Carcinoma (RCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Drugs used in chemotherapy, such as fluorouracil, work in different ways to stop tumor cells&#xD;
      from dividing so they stop growing or die. Suramin may increase the effectiveness of&#xD;
      fluorouracil by making tumor cells more sensitive to the drug. This phase I/II trial is&#xD;
      studying the side effects and best dose of fluorouracil and the chemosensitizer suramin and&#xD;
      to see how well they work in treating patients with metastatic renal cell (kidney) cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the dose of suramin and fluorouracil that would result in plasma concentrations&#xD;
      of suramin between 10-50 uM in patients with metastatic renal cell cancer. (Phase I) II.&#xD;
      Determine the objective response rate (complete response and partial response) in patients&#xD;
      treated with this regimen. (Phase II)&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the preliminary efficacy of this regimen in these patients. (Phase I) II.&#xD;
      Determine the pharmacokinetics of low-dose suramin in these patients. (Phase I) III.&#xD;
      Determine the time to tumor progression and progress rate at 3 and 6 months in patients&#xD;
      treated with this regimen. (Phase II)&#xD;
&#xD;
      OUTLINE: This is a dose-escalation phase I study followed by a phase II study.&#xD;
&#xD;
      PHASE I: Patients receive suramin IV over 30 minutes and fluorouracil IV on days 1, 8, 15,&#xD;
      22, 29, and 36. Cohorts of 3-6 patients receive escalating doses suramin and fluorouracil&#xD;
      until the dose level allowing 10-50 uM of suramin into the patient's blood is determined&#xD;
      without 2 or more of 6 patients experiencing dose-limiting toxicity.&#xD;
&#xD;
      PHASE II: Patients receive suramin and fluorouracil (at the dose level determined in phase I)&#xD;
      as in phase I.&#xD;
&#xD;
      In both phases, courses repeat every 8 weeks for up to 1 year in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed for survival.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose of suramin to deliver the target plasma concentrations of 10 to 50 uM (Phase I)</measure>
    <time_frame>Up to 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (CR + PR) using RECIST criteria (Phase II)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Summary statistics (e.g. means and standard deviations or medians and ranges, or frequency counts) and 95% confidence intervals will be calculated. Graphical models will also be used to summarize the data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression rate (Phase II)</measure>
    <time_frame>3 months</time_frame>
    <description>Summary statistics (e.g. means and standard deviations or medians and ranges, or frequency counts) and 95% confidence intervals will be calculated. Graphical models will also be used to summarize the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression rate (Phase II)</measure>
    <time_frame>6 months</time_frame>
    <description>Summary statistics (e.g. means and standard deviations or medians and ranges, or frequency counts) and 95% confidence intervals will be calculated. Graphical models will also be used to summarize the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression (Phase II)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Summary statistics (e.g. means and standard deviations or medians and ranges, or frequency counts) and 95% confidence intervals will be calculated. Graphical models will also be used to summarize the data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity assessed using NCI CTCAE version 3.0 (Phase II)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Summary statistics (e.g. means and standard deviations or medians and ranges, or frequency counts) and 95% confidence intervals will be calculated. Graphical models will also be used to summarize the data.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Recurrent Renal Cell Carcinoma</condition>
  <condition>Stage IV Renal Cell Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (suramin and fluorouracil)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PHASE I: Patients receive suramin IV over 30 minutes and fluorouracil IV on days 1, 8, 15, 22, 29, and 36. Cohorts of 3-6 patients receive escalating doses suramin and fluorouracil until the dose level allowing 10-50 uM of suramin into the patient's blood is determined without 2 or more of 6 patients experiencing dose-limiting toxicity.&#xD;
PHASE II: Patients receive suramin and fluorouracil (at the dose level determined in phase I) as in phase I.&#xD;
In both phases, courses repeat every 8 weeks for up to 1 year in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (suramin and fluorouracil)</arm_group_label>
    <other_name>5-Fluoro-2,4(1H, 3H)-pyrimidinedione</other_name>
    <other_name>5-Fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
    <other_name>AccuSite</other_name>
    <other_name>Actino-Hermal</other_name>
    <other_name>Adrucil</other_name>
    <other_name>Arumel</other_name>
    <other_name>Cytosafe</other_name>
    <other_name>Efudex</other_name>
    <other_name>Efurix</other_name>
    <other_name>Fiverocil</other_name>
    <other_name>Fluoro Uracil</other_name>
    <other_name>Fluoroplex</other_name>
    <other_name>Fluouracil</other_name>
    <other_name>Flurablastin</other_name>
    <other_name>Fluracedyl</other_name>
    <other_name>Fluracil</other_name>
    <other_name>Fluril</other_name>
    <other_name>Fluroblastin</other_name>
    <other_name>Flurox</other_name>
    <other_name>Ribofluor</other_name>
    <other_name>Ro 2-9757</other_name>
    <other_name>Ro-2-9757</other_name>
    <other_name>Timazin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (suramin and fluorouracil)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suramin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (suramin and fluorouracil)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed renal cell cancer&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
               -  Measurable disease required for phase II&#xD;
&#xD;
          -  No untreated CNS metastasis or CNS metastases progressing ≤ 4 weeks after prior&#xD;
             radiotherapy&#xD;
&#xD;
          -  Performance status - ECOG 0-1&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
          -  AST ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 5 times ULN&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.8 mg/dL&#xD;
&#xD;
          -  Calcium ≤ ULN&#xD;
&#xD;
          -  No untreated hypercalcemia&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must be surgically sterile or use effective contraception&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No known severe hypersensitivity to suramin&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  No active or ongoing infection&#xD;
&#xD;
          -  No active autoimmune disease&#xD;
&#xD;
          -  No neuropathy ≥ grade 2&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other malignancy within the past 5 years except basal cell skin cancer, carcinoma&#xD;
             in situ of the cervix, or localized prostate cancer&#xD;
&#xD;
          -  No concurrent filgrastim (G-CSF)&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens for renal cell cancer (phase II only)&#xD;
&#xD;
          -  No concurrent corticosteroid dose more than physiologic replacement levels&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  Recovered from prior oncologic or other major surgery&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
&#xD;
          -  No concurrent surgery&#xD;
&#xD;
          -  Recovered from all prior anticancer therapy other than alopecia (chronic toxicity &lt;&#xD;
             grade 2)&#xD;
&#xD;
          -  At least 4 weeks since prior systemic therapy&#xD;
&#xD;
          -  More than 30 days since prior investigational drugs&#xD;
&#xD;
          -  Concurrent bisphosphonates allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Bukowski</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>May 14, 2004</study_first_submitted>
  <study_first_submitted_qc>May 14, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2004</study_first_posted>
  <last_update_submitted>May 22, 2015</last_update_submitted>
  <last_update_submitted_qc>May 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suramin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

